| First Author | Ramani VC | Year | 2013 |
| Journal | FEBS J | Volume | 280 |
| Issue | 10 | Pages | 2294-306 |
| PubMed ID | 23374281 | Mgi Jnum | J:213103 |
| Mgi Id | MGI:5582882 | Doi | 10.1111/febs.12168 |
| Citation | Ramani VC, et al. (2013) The heparanase/syndecan-1 axis in cancer: mechanisms and therapies. FEBS J 280(10):2294-306 |
| abstractText | Heparanase is an endoglucuronidase that cleaves heparan sulfate chains of proteoglycans. In many malignancies, high heparanase expression and activity correlate with an aggressive tumour phenotype. A major consequence of heparanase action in cancer is a robust up-regulation of growth factor expression and increased shedding of syndecan-1 (a transmembrane heparan sulfate proteoglycan). Substantial evidence indicates that heparanase and syndecan-1 work together to drive growth factor signalling and regulate cell behaviours that enhance tumour growth, dissemination, angiogenesis and osteolysis. Preclinical and clinical studies have demonstrated that therapies targeting the heparanase/syndecan-1 axis hold promise for blocking the aggressive behaviour of cancer. |
